Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Britain Courts Anthropic Amid US Defense Department Dispute 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Apple Turns 50: From Garage Startup to AI Crossroads 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
PLEASANTON, Calif., Feb. 01, 2017 -- ZELTIQ® (Nasdaq:ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced that Mark Foley, President and Chief Executive Officer, and Taylor Harris, Senior Vice President and Chief Financial Officer, are scheduled to present at Leerink Partners 6th Annual Global Healthcare Conference in New York, NY. The Leerink Conference will utilize a fireside chat format for the presentation.
| Event: | Leerink Partners 6th Annual Global Healthcare Conference | ||
| Date: | Thursday, February 16, 2017 | ||
| Time: | 11:30 am ET | ||
Audio webcast of the Company’s presentation will be available by visiting the investor relations section of ZELTIQ’s web site at www.coolsculpting.com. A replay of the presentation will be available for 90 days.
About ZELTIQ® Aesthetics
ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ’s first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. It utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer.
MEDIA CONTACT: Jill Knepper Ketchum for ZELTIQ 310-437-2517 INVESTOR RELATIONS: Taylor Harris ZELTIQ, Senior Vice President and CFO 925-474-2500 Nick Laudico The Ruth Group for ZELTIQ 646-536-7030
